Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MHB036C plus MHB039A in advanced breast cancer and other malignancies
CTR20253136Phase 2Active
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MHB036C, MHB039A in breast cancer, Non-hematologic malignancy, sponsored by Minghui Pharmaceutical, Inc.. Started Aug 2025; status: active.
02
Drugs
MHB036CMHB039A
03
Conditions
breast cancerNon-hematologic malignancy
Beyond the preview
Go deeper on CTR20253136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253136.